Neurogene (NGNE) Expected to Announce Earnings on Friday

Neurogene (NASDAQ:NGNE - Get Free Report) is expected to post its Q1 2025 quarterly earnings results before the market opens on Friday, May 9th. Analysts expect Neurogene to post earnings of ($1.05) per share for the quarter.

Neurogene (NASDAQ:NGNE - Get Free Report) last released its quarterly earnings results on Monday, March 24th. The company reported ($0.99) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.04) by $0.05. The business had revenue of $0.93 million during the quarter. On average, analysts expect Neurogene to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Neurogene Stock Performance

NASDAQ:NGNE opened at $15.40 on Friday. Neurogene has a 1 year low of $6.88 and a 1 year high of $74.49. The stock has a market cap of $219.63 million, a price-to-earnings ratio of -3.61 and a beta of 1.46. The business has a fifty day moving average of $13.74 and a 200-day moving average of $23.22.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on NGNE shares. HC Wainwright cut their price objective on Neurogene from $55.00 to $50.00 and set a "buy" rating for the company in a report on Tuesday, March 25th. William Blair restated an "outperform" rating on shares of Neurogene in a report on Tuesday, March 25th. Robert W. Baird set a $38.00 price objective on Neurogene in a report on Tuesday, March 25th. Finally, BMO Capital Markets cut their price objective on Neurogene from $45.00 to $16.00 and set an "outperform" rating for the company in a report on Monday, April 14th. Six equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average target price of $47.20.

Insiders Place Their Bets

In other news, CFO Christine Mikail Cvijic sold 4,501 shares of Neurogene stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $16.94, for a total value of $76,246.94. Following the transaction, the chief financial officer now directly owns 72,343 shares of the company's stock, valued at $1,225,490.42. This trade represents a 5.86 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 9.92% of the company's stock.

About Neurogene

Neurogene Inc, a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.